CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026.

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the closing of the previously announced sale of its Lab Products business to Eurobio Scientific. The transaction closed on June 30, 2026 following receipt of required Swedish regulatory clearance.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx and FoundationOne®Liquid CDx to be used as companion diagnostics for Pfizer’s TALZENNA® (talazoparib) in combination with XTANDI® (enzalutamide) to identify patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). TALZENNA is first and only PARP inhibitor approved for use with an existing standard of care (XTANDI) for adult patients with both BRCA mutated and non-BRCA HRR gene-mutated mCRPC.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company developing immunotherapies to treat challenging and aggressive cancers. As part of the collaboration, Signatera will be used to longitudinally assess molecular response in patients with refractory melanoma enrolled in Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer’s disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer’s disease blood-based biomarker testing, with the LucentAD® Complete multi-biomarker blood test becoming available for neurologists to order on the Tempus clinical ordering platform.

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monitoring solution for viral‑mediated cancers. The transaction is an extension of CareDx’s strategy to focus on its U.S. Precision Medicine Testing Services and Patient and Digital Solutions. The definitive agreement provides for an up-front cash consideration of $160 million with up to an additional $100 million based on the achievement of revenue milestones.

Foundation Medicine, Inc., a global, patient-focused precision medicine company and an independent affiliate of Roche, announced it is set to expand its monitoring portfolio with SAGA Diagnostics’ tumor-informed molecular residual disease (MRD) platform as a result of Roche entering into a definitive merger agreement to acquire SAGA. Roche will pay a total of up to $595 million, inclusive of commercial and regulatory milestone payments. The transaction is subject to customary closing conditions including regulatory approvals, and is expected to close in Q3 2026, at the latest. Following the closing of the transaction, the platform will be fully integrated into Foundation Medicine.

Chinese molecular diagnostics and precision medicine firm GenePlus Technology said on Sunday that it has filed for an initial public offering on the Hong Kong Stock Exchange.